Eutilex

About Eutilex

Eutilex Co., Ltd. is a South Korean biopharmaceutical company operating in the clinical stage, with a focus on developing immunotherapeutic treatments for cancer and autoimmune diseases. The company was established in February 2015 by Byoung S. Kwon, Ph.D., an immunologist with an extensive academic background including a professorship at Indiana University's School of Medicine and postdoctoral work at Yale University. This foundation in immunology is central to the company's research and development direction. Eutilex became a public entity in December 2018, listing on the KOSDAQ exchange.

The company's business model is centered on the research, development, and eventual commercialization of its therapeutic pipelines, supplemented by strategic licensing agreements. A key agreement was established with China's Zhejiang Huahai Pharmaceutical, which included an equity stake and exclusive licensing for the development and commercialization of Eutilex's EU-101 antibody in Greater China. In 2024, Eutilex merged with INSystem, an IT firm specializing in healthcare data, a strategic move to integrate AI and data analytics into its drug development process. This acquisition has significantly impacted revenue, with a majority share now coming from the IT subsidiary, although the company maintains that drug development remains its primary long-term focus.

Eutilex’s product development is concentrated on three core platforms. The first is adoptive T-cell therapy, which involves isolating and culturing a patient's own T-cells to target and kill cancer cells; its lead candidate, 4-1BB CTL, has completed Phase 1 trials. The second platform is antibody therapeutics, developing monoclonal antibodies like EU-101, which activates the 4-1BB receptor on immune cells to stimulate an anti-tumor response. The third is Chimeric Antigen Receptor (CAR-T) therapy, a gene-editing approach to engineer T-cells to attack specific cancers, with its fourth-generation platform designed to overcome the challenges of treating solid tumors. The company also provides non-clinical contract research organization (CRO) services and is expanding into veterinary medicine with immune boosters for livestock.